outcome assessment

EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology
Delphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, Maarten de Wit, Bruno Fautrel, Thomas Frisell, Kimme L Hyrich, Florenzo Iannone, Pedro M Machado, Lykke Midtbøll Ørnbjerg, Ziga Rotar, Maria Jose Santos, Tanja A Stamm, Simon R Stones, Anja Strangfeld, Sytske Anne Bergstra, Robert B M Landewé, Axel Finckh

Annals of the Rheumatic Diseases Jun 2022, 81 (6) 780-785; DOI: 10.1136/annrheumdis-2021-221307
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
Pedro Lopez-Romero, Inmaculada de la Torre, Ewa Haladyj, Daniel Aletaha, Josef S Smolen

Annals of the Rheumatic Diseases May 2022, 81 (5) 622-631; DOI: 10.1136/annrheumdis-2021-221323
Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study
Denis Mongin, Kim Lauper, Axel Finckh, Thomas Frisell, Delphine Sophie Courvoisier

Annals of the Rheumatic Diseases May 2022, 81 (5) 729-736; DOI: 10.1136/annrheumdis-2021-221477
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
Xue Li, Xinning Tong, Winnie Wan Yin Yeung, Peng Kuan, Samson Hin Hei Yum, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Eric Yuk Fai Wan, Carlos King Ho Wong, Esther Wai Yin Chan, Chak Sing Lau, Ian Chi Kei Wong

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 564-568; DOI: 10.1136/annrheumdis-2021-221571
Response to: ‘Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis’ by Bugatti et al
Paul Studenic, David T Felson, Maarten de Wit, Josef S Smolen, Daniel Aletaha

Annals of the Rheumatic Diseases Apr 2022, 81 (4) e56; DOI: 10.1136/annrheumdis-2020-217705
Response to: Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment’ by Felson et al
David Felson, Diane Lacaille, Michael P LaValley, Daniel Aletaha

Annals of the Rheumatic Diseases Feb 2022, annrheumdis-2021-221941; DOI: 10.1136/annrheumdis-2021-221941
Time to reconsider what Global Burden of Disease studies really tell us about low back pain
Chris Maher, Giovanni Ferreira

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 306-308; DOI: 10.1136/annrheumdis-2021-221173
Challenges in optimising patient participation in research: do patients participating in meetings represent the actual patient population with Behçet’s syndrome?
Sıtkı Safa Taflan, Sinem Nihal Esatoglu, Yesim Ozguler, Berna Yurttas, Melike Melikoglu, Gulen Hatemi

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 448-450; DOI: 10.1136/annrheumdis-2021-221654
Baseline predictors of different types of treatment success in rheumatoid arthritis
Dafne Capelusnik, Daniel Aletaha

Annals of the Rheumatic Diseases Feb 2022, 81 (2) 153-158; DOI: 10.1136/annrheumdis-2021-220853
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study
Xiufang Kong, Ying Sun, Xiaojuan Dai, Li Wang, Zongfei Ji, Huiyong Chen, Xuejuan Jin, Lili Ma, Lindi Jiang

Annals of the Rheumatic Diseases Jan 2022, 81 (1) 117-123; DOI: 10.1136/annrheumdis-2021-220832

Main menu

outcome assessment

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

outcome assessment

Pages